Press release
Biliary Tumor Pipeline 2024 | FDA Approvals, Clinical Trials, Therapies, MOA, ROA by DelveInsight
Explore our latest breakthroughs in Biliary Tumor Research. Learn more about our innovative pipeline today! @ Biliary Tumor Pipeline Outlook [https://www.delveinsight.com/sample-request/biliary-tumor-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Key Takeaways from the Biliary Tumor Pipeline Report
* June 2024:- AstraZeneca- A Phase IIIb, Single Arm, Open-label, Multi-center Study on Durvalumab in Combination With Gemcitabine-based Chemotherapy as First Line Treatment for Chinese Patients With Unresectable Biliary Tract Cancers. This is a Phase IIIb, open-label, single arm, multicentre study to assess the safety and efficacy of durvalumab in combination with investigator's choice of 3 different gemcitabine-based chemotherapy regimens in participants with aBTC with a WHO/ECOG PS of 0 to 2 at enrolment.
* June 2024:- UNICANCER- Molecular Targeted Maintenance Therapy Versus Standard of Care in Advanced Biliary Cancer: an International, Randomised, Controlled, Open-label, Platform Phase 3 Trial. The object of this trial is to evaluate whether the introduction of a targeted therapy after 4 cycles of the current standard-of-care treatment for advanced biliary cancer is superior to continuing with the standard treatment.
* DelveInsight's Biliary Tumor pipeline report depicts a robust space with 50+ active players working to develop 55+ pipeline therapies for Biliary Tumor treatment.
* The leading Biliary Tumor Companies such as Jazz Pharmaceuticals, TransThera Sciences, Chia Tai Tianqing Pharmaceutical, Jiangsu HengRui Medicine, RemeGen, Shanghai Miracogen, ModeX Therapeutics, Intensity Therapeutics, GeneQuantum Healthcare, Elicio Therapeutics, SystImmune, Lanova Medicines Limited , and others.
* Promising Biliary Tumor Therapies such as Durvalumab, Futibatinib, Ivosidenib, Zanidatamab, Gemcitabine & Cisplatin, KN035, XmAb20717, ZW25 (Zanidatamab) , and others.
Stay informed about the cutting-edge advancements in Biliary Tumor Treatments. Download for updates and be a part of the revolution in cancer care @ Biliary Tumor Clinical Trials Assessment [https://www.delveinsight.com/sample-request/biliary-tumor-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Biliary Tumor Emerging Drugs Profile
* Rilvegostomig: AstraZeneca
Rilvegostomig (formerly AZD2936) is a bispecific antibody developed by AstraZeneca, targeting both PD-1 and TIGIT to enhance immune responses against cancer. Derived from Compugen's COM902 antibody, it aims to maximize the blockade of these pathways through cooperative binding, potentially improving therapeutic outcomes. Scheduled to progress into Phase III trials for indications like Biliary cancer, non-small cell lung cancer and gastric cancer, rilvegostomig is also being evaluated in combination with AstraZeneca's antibody-drug conjugates such as Enhertu, Dato-DXd, and AZD0901, as part of a strategy to leverage its differentiated bispecific format for greater efficacy.
* SHR-A1811: Jiangsu HengRui Medicine
SHR-A1811 is an antibody-drug conjugate (ADC) composed of trastuzumab, a cleavable linker, and a novel topoisomerase I inhibitor payload called SHR169265. It targets HER2-expressing tumor cells, delivering the cytotoxic payload upon internalization. Once inside the cell, the linker is cleaved, releasing SHR169265 which inhibits topoisomerase I, an essential enzyme for DNA replication and transcription, leading to cell cycle arrest and apoptosis. SHR-A1811 has shown promising antitumor activity in preclinical models and is currently being evaluated in multiple phase I-III clinical trials for HER2-positive and HER2-low breast cancer, gastric cancer, and other solid tumors. Currently, the drug is in Phase II stage of its clinical trial for the treatment of biliary cancer.
* AMG 193: Amgen
AMG 193 is a small molecule methylthioadenosine (MTA) cooperative protein arginine methyltransferase 5 (PRMT5) inhibitor. It is being investigated for the treatment of solid tumors. Currently, the drug is in Phase I stage of its clinical trial for the treatment of biliary cancer.
Learn more about Biliary Tumor Drugs opportunities in our groundbreaking Biliary Tumor Research and development projects @ Biliary Tumor Unmet Needs [https://www.delveinsight.com/sample-request/biliary-tumor-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Biliary Tumor pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.
* Oral
* Intravenous
* Subcutaneous
* Parenteral
* Topical
Products have been categorized under various Molecule types such as
* Recombinant fusion proteins
* Small molecule
* Monoclonal antibody
* Peptide
* Polymer
* Gene therapy
Discover the latest advancements in Biliary Tumor Treatment by visiting our website. Stay informed about how we're transforming the future of Oncology @ Biliary Tumor Market Drivers and Barriers, and Future Perspectives [https://www.delveinsight.com/sample-request/biliary-tumor-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Scope of the Biliary Tumor Pipeline Report
* Coverage- Global
* Biliary Tumor Companies- Jazz Pharmaceuticals, TransThera Sciences, Chia Tai Tianqing Pharmaceutical, Jiangsu HengRui Medicine, RemeGen, Shanghai Miracogen, ModeX Therapeutics, Intensity Therapeutics, GeneQuantum Healthcare, Elicio Therapeutics, SystImmune, Lanova Medicines Limited, and others.
* Biliary Tumor Therapies- Durvalumab, Futibatinib, Ivosidenib, Zanidatamab, Gemcitabine & Cisplatin, KN035, XmAb20717, ZW25 (Zanidatamab), and others.
* Biliary Tumor Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Biliary Tumor Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
For a detailed overview of our latest research findings and future plans, read the full details of Biliary Tumor Biliary Tumor Pipeline on our website @ Biliary Tumor Drugs and Companies [https://www.delveinsight.com/sample-request/biliary-tumor-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Table of Content
* Introduction
* Executive Summary
* Biliary Tumor: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Biliary Tumor- DelveInsight's Analytical Perspective
* Late Stage Products (Phase III)
* Rilvegostomig: AstraZeneca
* Drug profiles in the detailed report.....
* Mid Stage Products (Phase II)
* SHR-A1811: Jiangsu HengRui Medicine
* Drug profiles in the detailed report.....
* Early Stage Products (Phase I)
* AMG 193: Amgen
* Drug profiles in the detailed report.....
* Preclinical and Discovery Stage Products
* Drug name: Company name
* Drug profiles in the detailed report.....
* Inactive Products
* Biliary Tumor Key Companies
* Biliary Tumor Key Products
* Biliary Tumor- Unmet Needs
* Biliary Tumor- Market Drivers and Barriers
* Biliary Tumor- Future Perspectives and Conclusion
* Biliary Tumor Analyst Views
* Biliary Tumor Key Companies
* Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=biliary-tumor-pipeline-2024-fda-approvals-clinical-trials-therapies-moa-roa-by-delveinsight]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Biliary Tumor Pipeline 2024 | FDA Approvals, Clinical Trials, Therapies, MOA, ROA by DelveInsight here
News-ID: 3555485 • Views: …
More Releases from ABNewswire
How to Pick the Best Online Chemistry Tutoring Platform
Image: https://www.abnewswire.com/upload/2025/10/814f4b38d9855ce5fcc0509bfebaa240.jpg
Choosing the right chemistry tutoring platform can make the difference between academic success and continued struggles with complex reactions and molecular structures. With students increasingly turning to digital solutions for personalized learning support, the online chemistry tutoring market has exploded with options promising everything from AI-powered progress tracking to virtual lab experiences that transform how learners approach this challenging subject.
Essential Platform Features for Effective Online Chemistry Tutoring
Modern chemistry tutoring…
Chronic Myeloid Leukemia Pipeline Drugs Report 2025: Emerging Therapies, Clinica …
DelveInsight's "Chronic Myeloid Leukemia Pipeline Insight 2025" report provides comprehensive insights about 20+ companies and 20+ pipeline drugs in the Chronic Myeloid Leukemia pipeline landscape. It covers the Chronic Myeloid Leukemia Pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Chronic Myeloid Leukemia Pipeline Therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Curious…
Diabetic Retinopathy Pipeline Drugs Report 2025: Emerging Therapies, Clinical De …
DelveInsight's, "Diabetic Retinopathy Pipeline Insights 2025" report provides comprehensive insights about 50+ companies and 55+ pipeline drugs in the Diabetic Retinopathy pipeline landscape. It covers the Diabetic Retinopathy pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Diabetic Retinopathy pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore the comprehensive insights by…
Diabetic Macular Edema Pipeline Outlook Report 2025: Emerging Therapies, Clinica …
DelveInsight's, "Diabetic Macular Edema Pipeline Insight 2025" report provides comprehensive insights about 45+ companies and 50+ pipeline drugs in Diabetic Macular Edema pipeline landscape. It covers the Diabetic Macular Edema pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Diabetic Macular Edema pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore our…
More Releases for Biliary
Global Metal Pancreatic Biliary Stent Market Size by Application, Type, and Geog …
According to Market Research Intellect, the global Metal Pancreatic Biliary Stent market under the Internet, Communication and Technology category is expected to register notable growth from 2025 to 2032. Key drivers such as advancing technologies, changing consumer behavior, and evolving market dynamics are poised to shape the trajectory of this market throughout the forecast period.
The metal pancreatic biliary stent market is witnessing consistent growth due to the rising prevalence of…
Major Market Share Shift in Biliary Catheters Industry: Advancements In Biliary …
What Is the Forecasted Market Size and Growth Rate for the Biliary Catheters Market?
The market size for biliary catheters has experienced robust growth in recent years. There is an expected growth from $3.42 billion in 2024 to $3.75 billion in 2025, corresponding to a compound annual growth rate (CAGR) of 9.7%. Factors like increased occurrences of biliary tract ailments, the popularity of minimally invasive procedures, a growing aging population, more…
Primary Biliary Cholangitis Treatment Market
Primary Biliary Cholangitis Treatment Market
Global Primary Biliary Cholangitis Treatment Market Expected to Reach US$ YY Million by 2030, Growing at a CAGR of YY%: Market Insights and Dynamics
The Global Primary Biliary Cholangitis Treatment Market, which reached US$ YY billion in 2022, is anticipated to achieve US$ YY million by 2030, exhibiting a robust CAGR of YY% during the forecast period from 2024 to 2031.
Primary Biliary Cholangitis (PBC), formerly known as…
Biliary Stents Market - Unleashing Flow: Empowering Biliary Health with Innovati …
Newark, New Castle, USA - new report, titled Biliary Stents Market The report has been put together using primary and secondary research methodologies, which offer an accurate and precise understanding of the Biliary Stents market. Analysts have used a top-down and bottom-up approach to evaluate the segments and provide a fair assessment of their impact on the global Biliary Stents market. The report offers an overview of the market, which…
High Prevalence of Biliary Diseases Across the Globe is Driving the Biliary Sten …
Stent is referred as plastic or metal tube inserted in human body into lumen or duct to keep the passage open. Various types of stents such as expandable stents and simple plastic stents are used for various purposes. Different types of stents such as coronary, vascular, and biliary stents are employed for various purposes. ‘Biliary’ is referred to the bile duct, which is a long tube-like structure carrying bile fluid.…
Rise in Surgical Procedures of Biliary Diseases is Expected to Boost the Biliary …
Stent is referred as plastic or metal tube inserted in human body into lumen or duct to keep the passage open. Various types of stents such as expandable stents and simple plastic stents are used for various purposes. Different types of stents such as coronary, vascular, and biliary stents are employed for various purposes. ‘Biliary’ is referred to the bile duct, which is a long tube-like structure carrying bile fluid.…
